Chinese herbal medicine maker ramps up production to fight epidemic in HKSAR


Photo: CGV

Chinese drug producer Shijiazhuang Yiling Pharmaceutical, supplier of the famous Chinese herbal medicine Lianhua Qingwen, has increased production to provide much-needed treatment to the Hong Kong Special Administrative Region (HKSAR). The measure came as a response to the call to support the city to control the virus.

During the week of February 27 to March 5, an average of 42,188 cases were reported per day, compared to 13,913 daily cases the previous week, according to the latest report released by the Hong Kong SAR government, a jump by nearly 67% over one week. -week.

While the epidemic in Hong Kong remains severe, businesses on the mainland have stepped up efforts to support epidemic prevention and control measures.

Shijiazhuang Yiling Pharmaceutical is one of the companies that answered the call. Its patented Lianhua Qingwen capsules have been recommended for the treatment of COVID-19 by Chinese authorities and experts, making it the most recommended exclusive Chinese medicine.

Since the epidemic hit Hong Kong, the company has opened additional production lines to support the city’s anti-epidemic efforts, which have now grown to 17, the company said in an exclusive response to the Global Times on Sunday.

Lianhua Qingwen capsules produced for Hong Kong will mainly meet the needs of Hong Kong residents, the company said.

The Hong Kong non-governmental organization, Hong Kong Community Anti-Coronavirus Link, with members from all walks of life in Hong Kong, opened an online registration on Friday for residents to apply for 50,000 boxes of Lianhua Qingwen capsules as a help from the central government. at the HKSAR. Each person can request two boxes of medicine, media reported.

When registrations opened, Hong Kong residents rushed to the website which then crashed with the huge number of people trying to get a place. The recording lasted only 3.5 hours after opening.

The Hong Kong Community Anti-Coronavirus Link will order an additional 50,000 boxes of the drug, which are expected to arrive in Hong Kong as early as next week, according to media reports.

The production capacity provided by the company’s expanded production lines can continue to supply Hong Kong SAR to ensure Hong Kong residents have enough medicine, Shijiazhuang Yiling Pharmaceutical said Sunday.

Meanwhile, under the guidance, support and coordination of the Ministry of Industry and Information Technology, a green channel for Lianhua Qingwen has also been opened for the transportation of anti-epidemic materials, officials said. sources at the Global Times.

Medical supplies will be transported from Shenzhen to Hong Kong by train or truck.

Although Shijiazhuang Yiling Pharmaceutical could not give exact figures on the next delivery, production capacity has been fully increased and is confident of meeting local demand, the company said.


Comments are closed.